AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26010298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative volumetric measures of olfactory cleft opacification.
Number of subjects: 199
Study 26010610 — intervention group
Group type: COMPARATOR
Intervention: HFpEF patients
Number of subjects: 24
Study 26010610 — intervention group
Group type: COMPARATOR
Intervention: Metabolomic fingerprint
Number of subjects: 24
Study 26010778 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI and systemic chemotherapy
Number of subjects: 38
Study 26011015 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic rhinosinusitis (CRS) positive group
Number of subjects: 113
Study 26011015 — intervention group
Group type: COMPARATOR
Intervention: Chronic rhinosinusitis (CRS) negative group
Number of subjects: 113
Study 26011262 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine IP-10 levels
Number of subjects: 0
Study 26011265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 26011265 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 26011265 — intervention group
Group type: EXPERIMENTAL
Intervention: High Clopidogrel dose
Number of subjects: 0
Study 26011265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26011755 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexyl-5-aminolaevulinate 0·2%
Number of subjects: 0
Study 26011755 — intervention group
Group type: COMPARATOR
Intervention: methyl-5-aminolaevulinate 16%
Number of subjects: 0
Study 26011782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal manipulation (IM)
Number of subjects: 0
Study 26011782 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical study by Berdun et al.
Number of subjects: 0
Study 26014453 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention in a tobacco-free prison
Number of subjects: 247
Study 26014957 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose doripenem (5 mg/kg for <8 weeks and 8 mg/kg for ≥8 weeks) administered intravenously over 1 h
Number of subjects: 52
Study 26014957 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose doripenem
Number of subjects: 52
Study 26015411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 3 mg/kg (cohort 1)
Number of subjects: 65
Study 26015411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 2.5 mg/kg (cohort 2)
Number of subjects: 65
Study 26015411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 2 mg/kg (cohort 3)
Number of subjects: 65
Study 26015411 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (all cohorts)
Number of subjects: 65
Study 26015461 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 5%
Number of subjects: 0
Study 26015461 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 10%
Number of subjects: 0
Study 26015461 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss of 15%
Number of subjects: 0
Study 26015461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight loss)
Number of subjects: 0
Study 26016860 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MRI slice at lumbar vertebrae L3
Number of subjects: 142
Study 26016860 — intervention group
Group type: EXPERIMENTAL
Intervention: Single MRI slice at midthigh
Number of subjects: 142
Study 26016860 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (8.2 ± 5.2 kg) in 48 healthy volunteers
Number of subjects: 142
Study 26016863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anthocyanin intake
Number of subjects: 2375
Study 26016863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher flavonol intake
Number of subjects: 2375
Study 26016863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of apples and pears
Number of subjects: 2375
Study 26016863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of red wine
Number of subjects: 2375
Study 26016863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of strawberries
Number of subjects: 2375
Study 26016863 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of flavan-3-ols and their polymers
Number of subjects: 2375
Study 26016868 — intervention group
Group type: EXPERIMENTAL
Intervention: Opticourses intervention participants
Number of subjects: 91
Study 26017904 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS fatigue
Number of subjects: 120
Study 26017904 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcluster 1 (78% of total subjects)
Number of subjects: 120
Study 26017904 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcluster 2 (22% of total subjects)
Number of subjects: 120
Study 26018350 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg + Tocilizumab (TCZ)
Number of subjects: 10
Study 26018350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab and IVIg
Number of subjects: 10
Study 26018526 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Open Plating (MOP)
Number of subjects: 24
Study 26018526 — intervention group
Group type: COMPARATOR
Intervention: Conventional Open Plating (COP)
Number of subjects: 24
Study 26018967 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO (difluoromethylornithine) 500-1500 mg/m2 orally twice a day for three weeks, followed by DFMO plus daily oral etoposide for additional three-week cycles.
Number of subjects: 21
Study 26018967 — intervention group
Group type: EXPERIMENTAL
Intervention: DFMO therapy
Number of subjects: 21
Study 26019869 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBI
Number of subjects: 160
Study 26019869 — intervention group
Group type: COMPARATOR
Intervention: SBT
Number of subjects: 160
Study 26019883 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary interventions (PCIs) in 2013
Number of subjects: 2703
Study 26019883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reperfused patients in 2013
Number of subjects: 2703
Study 26019883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall STEMI mortality rate in 2013
Number of subjects: 2703
Study 26019881 — intervention group
Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 210
Study 26019881 — intervention group
Group type: COMPARATOR
Intervention: 64-multidetector CTCA
Number of subjects: 210
Study 26019881 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium score
Number of subjects: 210
Study 26020101 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine)
Number of subjects: 100
Study 26020107 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy
Number of subjects: 434
Study 26020107 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastrectomy
Number of subjects: 434
Study 26020125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 300 to 750 mg once daily in 21-day cycles
Number of subjects: 20
Study 26020125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg once daily (maximum-tolerated dose)
Number of subjects: 20
Study 26020123 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive PRF score based on seven independent risk factors: low preoperative SpO2; at least one preoperative respiratory symptom; preoperative chronic liver disease; history of congestive heart failure; open intrathoracic or upper abdominal surgery; surgical procedure lasting at least 2 hours; and emergency surgery.
Number of subjects: 5384
Study 26020123 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive PRF score
Number of subjects: 5384
Study 26020392 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop using interactive lecture, human model, educational film, and reference CPCR book
Number of subjects: 2000
Study 26020392 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 2000
Study 26020392 — intervention group
Group type: EXPERIMENTAL
Intervention: General population (G3)
Number of subjects: 2000
Study 26020392 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2000
Study 26020620 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarucizumab
Number of subjects: 0
Study 26020620 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26020762 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetSyn) group
Number of subjects: 77
Study 26020762 — intervention group
Group type: COMPARATOR
Intervention: Quantitative Insulin Sensitivity Check Index (as a surrogate for hepatic insulin sensitivity)
Number of subjects: 77
Study 26020762 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipo-SI and serum triglyceride levels
Number of subjects: 77
Study 26020762 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference and serum triglyceride levels
Number of subjects: 77
Study 26020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m plus Gemcitabine 1000 mg/m
Number of subjects: 18
Study 26020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 15 mg/m plus Gemcitabine 900 mg/m
Number of subjects: 18
Study 26020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 15 mg/m plus Gemcitabine 700 mg/m
Number of subjects: 18
Study 26020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 700 mg/m followed by Cabazitaxel 15 mg/m
Number of subjects: 18
Study 26020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus Gemcitabine (all doses)
Number of subjects: 18
Study 26020806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel plus Gemcitabine
Number of subjects: 18
Study 26021417 — intervention group
Group type: EXPERIMENTAL
Intervention: Proceed®-mesh
Number of subjects: 210
Study 26021444 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 39
Study 26021713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BMMCs) implantation
Number of subjects: 89
Study 26021959 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group A (specific acupoints along the stomach meridian)
Number of subjects: 706
Study 26021959 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 706
Study 26021959 — intervention group
Group type: COMPARATOR
Intervention: Itopride
Number of subjects: 706
Study 26021978 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM (lean diabetics)
Number of subjects: 63
Study 26021978 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (obese non-diabetics)
Number of subjects: 63
Study 26021978 — intervention group
Group type: COMPARATOR
Intervention: Control (lean non-diabetic)
Number of subjects: 63
Study 26022951 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free legislation
Number of subjects: 1651675
Study 26022951 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower RTI admissions
Number of subjects: 1651675
Study 26022951 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper RTI admissions
Number of subjects: 1651675
Study 26023175 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AF (PersAF)
Number of subjects: 323
Study 26023175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall AF burden
Number of subjects: 323
Study 26023175 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation episode frequency
Number of subjects: 323
Study 26023175 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure (HF) interaction with AF burden
Number of subjects: 323
Study 26023175 — intervention group
Group type: COMPARATOR
Intervention: Monitoring frequency and duration
Number of subjects: 323
Study 26024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Frisén grade assessment by lay readers
Number of subjects: 0
Study 26024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Frisén grade assessment by PRC
Number of subjects: 0
Study 26024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid pressure association with Frisén grade
Number of subjects: 0
Study 26024112 — intervention group
Group type: EXPERIMENTAL
Intervention: Frisén grade and fundus feature association with perimetric mean deviation
Number of subjects: 0
Study 26024473 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomass fuel users (wood, straw, crop residues, or dung)
Number of subjects: 12782
Study 26024473 — intervention group
Group type: COMPARATOR
Intervention: Clean fuel users (electricity, liquefied petroleum gas, natural gas, or biogas)
Number of subjects: 12782
Study 26024531 — intervention group
Group type: EXPERIMENTAL
Intervention: MiCK drug-induced apoptosis assay (used by physicians)
Number of subjects: 30
Study 26024661 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable artesunate
Number of subjects: 749
Study 26024661 — intervention group
Group type: COMPARATOR
Intervention: Injectable quinine
Number of subjects: 749
Study 26024688 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori seropositive individuals
Number of subjects: 4765
Study 26024688 — intervention group
Group type: COMPARATOR
Intervention: H. pylori seronegative individuals
Number of subjects: 4765
Study 26025012 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolfram Syndrome (WFS)
Number of subjects: 19
Study 26025012 — intervention group
Group type: COMPARATOR
Intervention: Type 1 Diabetes (T1DM)
Number of subjects: 19
Study 26025012 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 19
Study 26025572 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg od
Number of subjects: 777
Study 26025572 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 90 mg bid
Number of subjects: 777
Study 26025807 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine administered at 0, 2, and 6 months
Number of subjects: 38
Study 26025807 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY-CRM vaccine administered concomitantly at 0 months
Number of subjects: 38
Study 26025933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) at 10 mg/kg every 2 weeks, Temozolomide (TMZ) at 200 mg/m² per day on days 1-5, Irinotecan (CPT-11) at 125 mg/m² or 340 mg/m² every 2 weeks depending on antiepileptic drugs.
Number of subjects: 41
Study 26025965 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily and Everolimus 5 mg daily until disease progression, intolerable toxicity, investigator or patient decision.
Number of subjects: 35
Study 26026216 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH)
Number of subjects: 290
Study 26026264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative optical coherence tomography (OCT)
Number of subjects: 8
Study 26026390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 148
Study 26026738 — intervention group
Group type: EXPERIMENTAL
Intervention: hu3S193 (20mg/m² intravenously weekly for 8 weeks, up to 3 cycles)
Number of subjects: 31
Study 26026738 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 31
Study 26027940 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-source, constant-current, eight-contact DBS system
Number of subjects: 40
Study 26028255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient colorectal cancers
Number of subjects: 41
Study 26028255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-proficient colorectal cancers
Number of subjects: 41
Study 26028255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 14 days) in mismatch repair-deficient non-colorectal cancers
Number of subjects: 41
Study 26028255 — intervention group
Group type: COMPARATOR
Intervention: Mismatch repair-proficient tumors
Number of subjects: 41
Study 26028668 — intervention group
Group type: EXPERIMENTAL
Intervention: High mesothelin expression (defined as positivity in more than 25% of cells)
Number of subjects: 93
Study 26028668 — intervention group
Group type: EXPERIMENTAL
Intervention: High mesothelin expression
Number of subjects: 93
Study 26028965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide therapy
Number of subjects: 46
Study 26028965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-positive patients
Number of subjects: 46
Study 26028965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-negative patients
Number of subjects: 46
Study 26028965 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate using last observation carried forward
Number of subjects: 46
Study 26028965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-positive patients (last observation carried forward)
Number of subjects: 46
Study 26028965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide therapy in JAK2-negative patients (last observation carried forward)
Number of subjects: 46
Study 26030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular performance
Number of subjects: 403
Study 26030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor performance (MP)
Number of subjects: 403
Study 26030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%)
Number of subjects: 403
Study 26030086 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat percentage (BF%) with poorest MP
Number of subjects: 403
Study 26030086 — intervention group
Group type: COMPARATOR
Intervention: Cardiorespiratory performance (CP)
Number of subjects: 403
Study 26030696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) on quantitative emphysema and airway imaging phenotypes
Number of subjects: 12031
Study 26030696 — intervention group
Group type: COMPARATOR
Intervention: Previously reported COPD and spirometric loci
Number of subjects: 12031
Study 26030709 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral anterior nuclear stimulation with Medtronic Activa PC+S device
Number of subjects: 2
Study 26030709 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of AN electrodes using a novel trajectory
Number of subjects: 2
Study 26030709 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative stimulation of the anterior nucleus
Number of subjects: 2
Study 26031269 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized irrigation
Number of subjects: 132
Study 26031269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincision gentamicin injection
Number of subjects: 132
Study 26031269 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention groups (pressurized irrigation and gentamicin)
Number of subjects: 132
Study 26031269 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 26031410 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPK modeling and classical population PK modeling
Number of subjects: 0
Study 26031410 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based approaches for drug development
Number of subjects: 0
Study 26031410 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based predictions
Number of subjects: 0
Study 26031893 — intervention group
Group type: EXPERIMENTAL
Intervention: iVATS (image-guided video-assisted thoracoscopic surgery)
Number of subjects: 25
Study 26031893 — intervention group
Group type: EXPERIMENTAL
Intervention: iVATS
Number of subjects: 25
Study 26032537 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional immunosuppression
Number of subjects: 0
Study 26032537 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapies
Number of subjects: 0
Study 26032537 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging pathways and therapeutic agents
Number of subjects: 0
Study 26032890 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state MEG-independent component analysis (ICA) technique
Number of subjects: 0
Study 26033209 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook recruitment strategy
Number of subjects: 1023
Study 26033282 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD 300 mg/day given orally starting 7 days before transplantation until day 30
Number of subjects: 48
Study 26033282 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD plus standard GVHD prophylaxis
Number of subjects: 48
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse photoplethysmographic amplitude (PPGA)
Number of subjects: 10
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS state (ANSS)
Number of subjects: 10
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: ANS index (ANSSi)
Number of subjects: 10
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV)
Number of subjects: 10
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: Baroreflex sensitivity
Number of subjects: 10
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse photoplethysmographic indices
Number of subjects: 10
Study 26035252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathovagal modulation directed to the heart
Number of subjects: 10
Study 26036953 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic Voluntary Hyperventilation (EVH) testing
Number of subjects: 10
Study 26036953 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Number of subjects: 10
Study 26037515 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for acromegaly
Number of subjects: 23
Study 26037794 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D) implant
Number of subjects: 4800
Study 26038121 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiling of CD19(+)CD5(+)-B-lymphocytes
Number of subjects: 216
Study 26038521 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of stroke
Number of subjects: 4232
Study 26038521 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental history of stroke
Number of subjects: 4232
Study 26038537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D) in patients with GFR <60
Number of subjects: 1820
Study 26038537 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D) in patients with GFR ≥60
Number of subjects: 1820
Study 26038537 — intervention group
Group type: COMPARATOR
Intervention: Non-left bundle-branch block patients
Number of subjects: 1820